トウケイブ ヘンペイ ジョウヒ ガン ニ オイテ microRNA-29s ワ ラミニン インテグリン ケイロ オ セイギョ スル コト ニ ヨリ ガン サイボウ ノ ユウソウ シンジュン オ ヨクセイ スル by 木下, 崇 & KINOSHITA, Takashi
Tumour-suppressive microRNA-29s inhibit cancer cell migration and 
invasion by targeting laminin-integrin signalling in head and neck 
squamous cell carcinoma
（頭頸部扁平上皮癌において microRNA-29s はラミニン・
インテグリン経路を制御する事により
癌細胞の遊走・浸潤を抑制する。）
千葉大学大学院医学薬学府
先進医療科学専攻 耳鼻咽喉科学
（主任：岡本美孝教授）
木下 崇
1Tumour-suppressive microRNA-29s inhibit cancer cell migration and invasion by targeting 
laminin-integrin signalling in head and neck squamous cell carcinoma
Running title: miR-29s target laminin-integrin in HNSCC
Takashi Kinoshita1,2, Nijiro Nohata1,2, Toyoyuki Hanazawa2, 
Naoko Kikkawa2, Noriko Yamamoto1, Hirofumi Yoshino3, 
Toshihiko Itesako3, Hideki Enokida3, Masayuki Nakagawa3, 
Yoshitaka Okamoto2, Naohiko Seki1,#
1Department of Functional Genomics, Graduate School of Medicine, Chiba University, Chiba, 
Japan
2Department of Otorhinolaryngology/Head and Neck Surgery, Chiba University Graduate 
School of Medicine, Chiba, Japan 
3Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima 
University, Kagoshima, Japan
#Correspondence to:
Naohiko Seki, Ph.D.
Associate Professor of Functional Genomics,
Department of Functional Genomics,
Chiba University Graduate School of Medicine,
1-8-1 Inohana Chuo-ku, Chiba 260-8670, Japan
Tel: +81-43-226-2971
Fax: +81-43-227-3442
E-mail: naoseki@faculty.chiba-u.jp
2Abstract
Background: Our recent studies of microRNA (miRNA) expression signatures demonstrated 
that microRNA-29s (miR-29s; miR-29a/b/c) were significantly downregulated in head and neck 
squamous cell carcinoma (HNSCC) and were putative tumour suppressive miRNAs in human 
cancers. Our aim in this study was to investigate the functional significance of miR-29s in 
cancer cells and to identify novel miR-29s-mediated cancer pathways and responsible genes in 
HNSCC oncogenesis and metastasis.
Methods: Gain-of-function studies using mature miR-29s were performed to investigate cell 
proliferation, migration and invasion in two HNSCC cell lines (SAS and FaDu). To identify 
miR-29s-mediated molecular pathways and targets, we utilised gene expression analysis and in 
silico database analysis. Loss-of-function assays were performed to investigate the functional 
significance of miR-29s target genes.
Results: Restoration of miR-29s in SAS and FaDu cell lines revealed significant inhibition of 
cancer cell migration and invasion. Gene expression data and in silico analysis demonstrated 
that miR-29s modulated the focal adhesion pathway. Moreover, laminin 2 (LAMC2) and 6
integrin (ITGA6) genes were candidate targets of miR-29s’ regulation. Luciferase reporter 
assays showed that miR-29s directly regulated LAMC2 and ITGA6. Silencing of LAMC2 and 
ITGA6 genes significantly inhibited cell migration and invasion in cancer cells.
Conclusions: Downregulation of miR-29s was a frequent event in HNSCC. miR-29s acted as 
tumour suppressors and directly targeted laminin-integrin signalling. Recognition of tumour
suppressive miRNA-mediated cancer pathways provides new insights into the potential 
mechanisms of HNSCC oncogenesis and metastasis and suggests novel therapeutic strategies 
for the disease.
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3Introduction
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer in 
the world and approximately 500,000 cases are diagnosed every year (Jemal et al, 2010). In 
spite of considerable advances in multimodality therapy, including surgery, radiotherapy and 
chemotherapy, the overall five-year survival rate for patients with HNSCC is only 40 - 50% 
(Leemans et al, 2011). Local tumour recurrence and distant metastasis after conventional 
therapy appear to be major contributing factors for restricted survival of HNSCC patients. 
Therefore, understanding the molecular pathways of metastasis accompanying HNSCC would 
help to improve diagnosis, approaches to therapy and prevention of the disease.
The discovery of non-coding RNAs in the human genome was an important conceptual 
breakthrough in the post-genome sequencing era (Mattick, 2004). microRNAs (miRNAs)
constitute a class of small, non-coding RNA molecules (19 – 22 nucleotides in length) that
regulate protein-coding gene expression by repressing translation or cleaving RNA transcripts in 
a sequence-specific manner (Bartel, 2004). miRNAs are unique in their ability to regulate 
multiple protein-coding genes. Bioinformatic predictions indicate that miRNAs regulate more 
than 30% of the protein-coding genes in the human genome (Lewis et al, 2005).
A growing body of evidence suggests that miRNAs contribute significantly to HNSCC 
progression, development and metastasis (Esquela-Kerscher and Slack, 2006). In cancer 
pathways, normal regulatory mechanisms are disrupted by altered expression of 
tumour-suppressive or oncogenic miRNAs. Therefore, identification of differentially expressed 
miRNAs is an important step to understand human oncogenesis. Genome-wide miRNA 
expression signatures have been used to rapidly and precisely identify aberrant miRNA 
expression in HNSCC. Based on recent reports, including our own signatures, several down- or 
upregulated miRNAs have been discovered in HNSCC (Avissar et al, 2009; Hui et al, 2010; 
Kikkawa et al, 2010; Nohata et al, 2011).
     Our expression signature of HNSCC demonstrated that the microRNA-29 family 
(miR-29s) was downregulated in cancer tissues (Kikkawa et al, 2010; Nohata et al, 2011). The 
miR-29s include three members, miR-29a, miR-29b and miR-29c in the human genome. 
miR-29b includes two members, miR-29b-1 and miR-29b-2 (Wang et al, 2013). These miRNAs 
form clusters on two human genome loci: miR-29b-1 and miR-29a in 7q32 and miR-29b-2 and 
miR-29c in 1q32 (Kriegel et al, 2012). Although aberrant expression of miR-29s was reported in 
several types of human cancers, the expression status of miR-29s varied according to the cancer 
types (Fabbri et al, 2007; Fu et al, 2012; Gebeshuber et al, 2009; Han et al, 2010; Li et al, 2011; 
Mott et al, 2010; Presneau et al, 2013; Sengupta et al, 2008; Xiong et al, 2010; Zhao et al, 
2010). Therefore, the aim of this study was to investigate the functional significance of the 
miR-29s in cancer cells and to identify novel miR-29s-regulated cancer pathways and 
4responsible genes in HNSCC oncogenesis and metastasis.
Genome-wide gene expression analysis of miR-29a transfectants and in silico database 
analysis showed that the focal adhesion pathway was a promising candidate target pathway. In 
this regard, laminin-integrin signalling is critically important. It occurs in the basal lamina and 
influences cell differentiation, migration and adhesion as well as proliferation and cell survival. 
Interestingly, laminin 2 (coded by LAMC2), a member of laminin-332, and 6 integrin (coded 
by ITGA6) were listed as candidate genes in the focal adhesion pathway. Moreover, interaction 
between laminin-332 and 64 integrin triggers a number of signalling cascades, promoting 
both cell migration and cancer cell survival (Kariya et al, 2009; Marinkovich, 2007). We 
investigated the functional significance of LAMC2 and ITGA6 in HNSCC and showed that these 
genes were regulated by miR-29s. The identification of novel cancer pathways regulated by 
tumour suppressive miR-29s provides new insights into the potential mechanisms of HNSCC 
oncogenesis and metastasis.
5Materials and Methods
Clinical HNSCC specimens
Twenty-three pairs of primary HNSCC and corresponding normal epithelial samples were 
obtained from patients with HNSCC at Chiba University Hospital (Chiba, Japan) from 2005 to 
2011. The samples considered normal were free of cancer cells by pathologic examination. The 
patients’ backgrounds and clinico-pathological characteristics are summarised in Supplementary 
table 1. The patients were classified according to the 2002 Union for International Cancer 
Control (UICC) TNM staging criteria prior to treatment. Written consent for tissue donation for 
research purposes was obtained from each patient before tissue collection. The protocol was 
approved by the Institutional Review Board of Chiba University. The specimens were immersed 
in RNAlater (Qiagen, Valencia, CA, USA) and stored at -20°C until RNA was extracted.
RNA isolation
Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the 
manufacturer’s protocol. RNA concentrations were determined spectrophotometrically, and 
molecular integrity was checked by gel electrophoresis. RNA quality was confirmed using an 
Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).
HNSCC cell culture
The following human HNSCC cell lines were used: SAS (derived from a primary lesion of 
tongue SCC) and FaDu (derived from a primary lesion of hypopharyngeal SCC). Both cell lines 
were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal 
bovine serum in a humidified atmosphere containing 5% CO2 at 37°C.
Quantitative real-time RT-PCR (qRT-PCR)
First-strand cDNA was synthesized from one μg of total RNA using a High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). Gene-specific PCR 
products were assayed continuously using a 7900-HT Real-Time PCR System according to the 
manufacturer’s protocol. The initial PCR step consisted of a ten min hold at 95°C, followed by 
40 cycles consisting of a 15 sec denaturation at 95°C and a one min annealing/extension at 60°C. 
The expression levels of miR-29a (Assay ID: 002112), miR-29b (Assay ID: 000413) and 
miR-29c (Assay ID: 000587) were analysed by TaqMan quantitative real-time PCR (TaqMan® 
MicroRNA Assay; Applied Biosystems) and normalised to RNU48 (Assay ID: 001006). 
TaqMan® probes and primers for, LAMC2 (P/N: Hs01043711_m1), ITGA6 (P/N: 
Hs01041011_m1) and GUSB (P/N: Hs99999908_m1) as an internal control were obtained from 
Applied Biosystems (Assay-On-Demand Gene Expression Products). The delta delta Ct method 
6was adopted and applied to calculate the relative quantities of subject genes. All reactions were 
performed in triplicate, and included negative control reactions that lacked cDNA.
Mature miRNA transfection and small interfering RNA treatment
The following mature miRNAs species were used in this study: mirVanaTM miRNA mimic for
hsa-miR-29a-3p (Product ID: MC12499), hsa-miR-29b-3p (Product ID: MC10103) and 
hsa-miR-29c-3p (Product ID: MC10518) (Applied Biosystems). The following siRNAs were 
used: Stealth Select RNAi™ siRNA; si-LAMC2 (Cat# HSS105965), si-ITGA6 (Cat# 
HSS179959) (Invitrogen) and negative control miRNA/siRNA (P/N: AM17111, Applied 
Biosystems). RNAs were incubated with OPTI-MEM (Invitrogen) and LipofectamineTM 
RNAiMax reagent (Invitrogen) as described previously (Ichimi et al, 2009). Transfection 
efficiency of miRNA in cell lines was confirmed based on downregulation of TWF1 (PTK9) 
mRNA following transfection with miR-1 as previously reported (Ichimi et al, 2009).
Cell proliferation, migration and invasion assays
Cells were transfected with ten nM miRNA or siRNA by reverse transfection and plated in 
96-well plates at 3 x 103 cells per well. After 72 h, cell proliferation was determined with the 
XTT assay, using the Cell Proliferation Kit II (Roche Molecular Biochemicals, Mannheim, 
Germany) as previously reported (Chiyomaru et al, 2010). 
A cell migration assay was performed using BD FalconTM Cell Culture Inserts (BD Biosciences, 
Franklin Lakes, NJ, USA) that contained uncoated Transwell polycarbonate membrane filters
with eight μm pores in 24-well tissue culture plates. Cells were transfected with ten nM miRNA
or siRNA by reverse transfection and plated in ten cm dishes at 8 × 105 cells. After 48 h, the 
cells were collected and 2 x 105 cells were added to the upper chamber of each migration well 
and were allowed to migrate for 48 h. After gentle removal of the nonmigratory cells from the 
filter surface of the upper chamber, the cells that migrated to the lower side were fixed and 
stained with Diff-Quick (Sysmex Corporation, Japan). The number of cells that migrated to the 
lower surface was determined microscopically by counting four areas of constant size per well.
A cell invasion assay was carried out using modified Boyden chambers containing 
Transwell-precoated Matrigel membrane filter inserts with eight μm pores in 24-well tissue 
culture plates at 2 x 105 cells per well (BD Biosciences). All experiments were performed in 
triplicate.
In silico analysis, genome-wide gene expression analysis and miR-29s target search.
To identify miR-29s target genes, we used in silico analysis and genome-wide gene expression 
analysis. First, we screened genes using TargetScan Release 6.2 (http://www.targetscan.org/). 
7These genes were then categorised into KEGG (Kyoto Encyclopedia of Genes and Genomes) 
pathways using GENECODIS analysis (Tabas-Madrid et al, 2012)
(http://genecodis.cnb.csic.es/). To identify upregulated genes in HNSCC we analysed a publicly
available gene expression data set in GEO (accession number: GSE9844). To gain further 
insight into which genes were affected by miR-29s, we performed genome-wide gene 
expression analysis using miR-29a transfection of SAS. SurePrint G3 Human GE 8x60K 
Microarray (Agilent Technologies) was used for expression profiling of miR-29a transfectants in 
comparison with negative control miRNA transfectants.
Western blotting
Cells were harvested 72 h after transfection and lysates were prepared. Fifty μg of protein from
each lysate were separated on a Mini-PROTEAN TGX gel (Bio-Rad, Hercules, CA, USA) and 
transferred to PVDF membranes. Immunoblotting was performed with mouse LAMC2
antibody (1:500, MAB19562, Merck Millipore, Billerica, MA, USA) and rabbit ITGA6 
antibody (1:1000, ab97760, Abcam, UK) with GAPDH antibody (1:1000, ab8245, Abcam) used 
as an internal control. The membrane was washed and incubated with anti-mouse IgG 
HRP-linked antibody (#7076, Cell Signaling Technology, Danvers, MA, USA) or anti-rabbit 
IgG HRP-linked antibody (#7074, Cell Signaling Technology). Complexes were visualized with 
an Immun-StarTM WesternC Chemiluminescence Kit (Bio-Rad), and the expression levels of 
these genes were evaluated by ImageJ software (ver.1.44; http://rsbweb.nih.gov/ij/).
Plasmid construction and dual-luciferase reporter assay
The partial wild-type sequences of the LAMC2 3’-untranslated region (3’-UTR) or those with 
deleted miR-29s target sites (Position 611-627 and 1430-1436 of LAMC2 3’-UTR) were inserted 
between the XhoI–PmeI restriction sites in the 3’-UTR of the hRluc gene in psiCHECK-2 
vector (C8021; Promega, Madison, WI, USA). The same was done with the partial wild-type 
sequences of the ITGA6 3’-UTR or those with deleted miR-29s target site (Position 1570-1576 
of ITGA6 3’-UTR). The sequences of the oligonucleotides were described in Supplementary 
document 1. SAS cells were transfected with five ng of vector and ten nM of miR-29s using 
Lipofectamine 2000 (Invitrogen). The activities of firefly and Renilla luciferases in cell lysates 
were determined with a dual-luciferase assay system (E1910; Promega). Normalised data were 
calculated as the quotient of Renilla/firefly luciferase activities.
Statistical analysis
The relationships between two groups and the numerical values obtained by real-time RT-PCR 
were analysed using the paired t-test. Spearman’s rank test was used to evaluate the correlation 
8between the expressions of miR-29s. The relationship among more than three variables and 
numerical values were analysed using the Bonferroni adjusted Mann-Whitney U test. All 
analyses were performed using Expert StatView (version 4, SAS Institute Inc., Cary, NC, USA).
9Results
Expression of miR-29s in clinical HNSCC specimens
The chromosomal locations of miR-29s in the human genome are shown in 
Supplementary figure 1. These miRNAs are clustered at two different human genomic loci, 
miR-29b-1 and miR-29a at 7q32.3 and miR-29b-2 and miR-29c at 1q32.2.
To validate our past miRNA profiling results, we evaluated miR-29s expression in 23 
clinical HNSCC specimens. The expression levels of miR-29a, miR-29b and miR-29c were 
significantly lower in tumour tissues than in corresponding adjacent non-cancerous epithelia (P
= 0.029, P = 0.034 and P < 0.0001, respectively, Figure 1A). Spearman’s rank test showed
positive correlation between the expression of miR-29a and that of miR-29b (R = 0.55 and P = 
0.0001, Figure 1B). Similarly, the expression of miR-29c was positively correlated with that of 
miR-29b (R = 0.62 and P < 0.0001, Figure 1B).
Effect of restoring miR-29s on cell proliferation, migration and invasion activities in 
HNSCC cell lines
To investigate the functional effects of miR-29s, we performed gain-of-function studies 
using miRNA transfection of SAS and FaDu cell lines. The XTT assay demonstrated that cell 
proliferation was significantly inhibited in miR-29s transfectants in comparison with the mock 
or miR-control transfectant cells. Specifically, we observed the following growth, expressed as a 
percentage of the mock: (1) SAS -- Mock, 100.0 ± 2.4; miR-control, 110.8 ± 4.9; miR-29a, 48.6
± 4.2; miR-29b, 56.4 ± 5.0; miR-29c, 60.7 ± 4.9; (2) FaDu --  Mock, 100.0 ± 1.9; miR-control, 
104.5 ± 2.6; miR-29a, 82.3 ± 4.4; miR-29b, 84.5 ± 1.8; miR-29c, 62.7 ± 0.7, with P < 0.005 for 
both (Figure 2A).
The migration assay demonstrated that cell migration activity was significantly inhibited 
in miR-29s transfectants in comparison with the mock or miR-control transfectant cells. 
Specifically, we observed the following migration activities, expressed as a percentage of the 
mock: (1) SAS -- Mock, 100.0 ± 5.3; miR-control, 100.2 ± 4.8; miR-29a, 10.2 ± 1.3; miR-29b, 
7.9 ± 0.9; miR-29c, 5.2 ± 0.8; (2) FaDu --  Mock, 100.0 ± 8.7; miR-control, 113.4 ± 13.8; 
miR-29a, 8.3 ± 4.4; miR-29b, 14.0 ± 4.0; miR-29c, 8.6 ± 2.3, with  P < 0.005 for both (Figure 
2B).
The Matrigel invasion assay demonstrated that cell invasion activity was significantly 
inhibited in miR-29s transfectants in comparison with the mock or miR-control transfectant cells. 
Specifically, we observed the following migration activities, expressed as a percentage of the 
mock: (1) SAS -- Mock, 100.0 ± 13.6; miR-control, 99.2 ± 11.4; miR-29a, 11.1 ± 2.8; miR-29b, 
6.9 ± 1.8; miR-29c, 6.4 ± 1.8 and (2) FaDu --  Mock, 100.0 ± 16.3; miR-control, 94.9 ± 4.4; 
miR-29a, 5.8 ± 1.8; miR-29b, 10.9 ± 2.0; miR-29c, 8.3 ± 2.2, with  P < 0.005 for both (Figure 
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2C).
Selection of candidate genes targeted by miR-29s
To identify genes targeted by miR-29s, we used in silico analysis and genome-wide gene 
expression analysis. Our strategy for selection of miR-29s-targeted genes is shown in 
Supplementary figure 2. First, we screened miR-29s-targeted genes using the TargetScan 
database and identified 2,627 genes (Supplementary table 2). These genes were then categorised 
into KEGG pathways using GENECODIS analysis and 83 pathways were identified as 
significantly enriched pathways (Supplementary table 3). Among those pathways, we focused 
on the focal adhesion pathway because this pathway was implicated in cancer cell migration and 
invasion. A total of 58 genes was identified in this pathway (Supplementary table 4). The gene 
set was then analysed with a publicly available gene expression data set in GEO (accession 
number: GSE9844) and genes upregulated (log2 ratio > 0.5) in HNSCC were chosen. To gain 
further insight into which genes were affected by miR-29s, we performed genome-wide gene 
expression analysis using SAS, and genes downregulated (log2 ratio < -0.5) by miR-29a
transfection were selected. Entries from the gene expression data were approved by GEO, and 
were assigned GEO accession number GSE47657. As a result, 16 candidate genes were 
identified as miR-29s targets in the focal adhesion pathway (Table 1). Among those candidates, 
we focused on LAMC2 (a component of laminin-332), which is a specific ligand of ITGA6 (a 
component of 6 4 integrin). Laminin 332-64 integrin interaction is known to promote 
tumour invasion and cell survival through PI3K and RAC1 activation. Therefore, we focused on 
LAMC2 and ITGA6 in further analyses.
LAMC2 and ITGA6 were directly regulated by miR-29s
We performed qRT-PCR and Western blotting in SAS to investigate whether LAMC2 and 
ITGA6 expression was downregulated by restoration of miR-29s. The mRNA and protein 
expression levels of LAMC2/LAMC2 were significantly repressed in miR-29s transfectants in 
comparison with mock or miR-control transfectants (P < 0.005, Figure 3A and 3B). Similarly, 
the mRNA and protein expression levels of ITGA6/ITGA6 were significantly repressed in 
miR-29s transfectants (P < 0.005, Figure 4A and 4B).
We performed a luciferase reporter assay in SAS to determine whether LAMC2 and 
ITGA6 mRNA had target sites for miR-29s. The TargetScan database predicted that two putative 
miR-29s binding sites existed in LAMC2 3’-UTR (position 611 - 627 and 1430 - 1436, Figure 
3C). We used vectors encoding either the partial wild-type sequence of the 3’-UTR of LAMC2
mRNA, including the predicted miR-29s target sites or “deletion” vectors, i.e., those lacking the 
miR-29s target sites. We found that the luminescence intensity was significantly reduced by 
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transfection of miR-29s with the vector carrying the wild-type 3’-UTR of LAMC2 whereas 
transfection with deletion vectors (positions 611 - 627 or 1430 - 1436 had been removed) 
blocked the decrease in luminescence (P < 0.0083, Figure 3D). As for ITGA6, the TargetScan 
database predicted a putative miR-29s binding site in ITGA6 3’-UTR (position 1570 - 1576). We 
constructed a vector encoding either the partial wild-type sequences of 3’-UTR of ITGA6 or 
those with a deleted miR-29s target site (Figure 4C). The luminescence intensity was 
significantly reduced by transfection of miR-29s with the vector of wild-type 3’-UTR of LAMC2
(P < 0.0083, Figure 4D). Although the luminescence intensity was also reduced by transfection 
of miR-29s with the deletion vector, the reduction was smaller than that with wild-type (Figure 
4D).
Effects of silencing LAMC2 and ITGA6 on cell proliferation, migration and invasion in 
SAS
To investigate the functional role of LAMC2 and ITGA6, we performed loss-of-function 
studies using si-LAMC2 and si-ITGA6 transfectants. First, we evaluated the knockdown 
efficiency of si-LAMC2 and si-ITGA6 treatments in SAS. qRT-PCR and Western blotting 
indicated that the two siRNAs effectively downregulated LAMC2 and ITGA6 expression in SAS 
(Supplementary figure 3).
The XTT assays demonstrated that cell proliferation was significantly inhibited in 
si-LAMC2 transfectants in comparison with the mock or si-control transfectant in SAS
(percentage of the mock: 64.7 ± 2.2, with P < 0.0167; Figure 5A). On the other hand, 
proliferation was not inhibited in si-ITGA6 transfectants in comparison with the mock or 
si-control transfectants in SAS (Figure 5B).
The migration assays demonstrated that cell migration activity was significantly inhibited 
in both si-LAMC2 and si-ITGA6 transfectants in comparison with the mock or si-control 
transfectants in SAS (percentage of the mock: si-LAMC2, 14.3 ± 7.2; si-ITGA6, 15.8 ± 12.5,
with P < 0.0167 for both; Figure 5C and 5D).
Matrigel invasion assays demonstrated that cell invasion activity was significantly 
inhibited in both si-LAMC2 and si-ITGA6 transfectants in comparison with the mock or 
si-control transfectants in SAS (percentage of the mock: si-LAMC2, 23.4 ± 14.0; si-ITGA6, 19.6 
± 14.3, with P < 0.0167 for both; Figure 5E and 5F).
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Discussion
In the post-genome sequencing era, improved understanding of non-coding RNA is 
necessary for continued progress in cancer research. For elucidation of the molecular 
mechanisms underlying HNSCC, we have examined tumour suppressive miRNAs, focusing on 
their regulated molecular targets and novel cancer pathways based on HNSCC expression 
signatures (Kikkawa et al, 2010; Nohata et al, 2011). Our previous miRNA expression 
signatures demonstrated that the miR-29s family (miR-29a/b/c) was reduced in several types of 
cancers (Kikkawa et al, 2010; Nohata et al, 2011). Decreased expression of miR-29s was 
described in other types of cancers such as cholangiocarcinoma, nasopharyngeal cancer,
non-small cell lung cancer, cervical cancer, hepatocellular carcinoma, malignant peripheral 
nerve sheath tumour and mantle cell lymphoma (Fabbri et al, 2007; Li et al, 2011; Mott et al, 
2010; Presneau et al, 2013; Xiong et al, 2010; Zhao et al, 2010), all of which is consistent with 
our results. In contrast, upregulation of miR-29s was reported in breast cancer, colon cancer and 
acute myeloid leukaemia (Fu et al, 2012; Gebeshuber et al, 2009; Han et al, 2010). Therefore,
the molecular mechanisms by which miR-29s expression is deregulated vary according to cancer 
types. In this study, our data showed that all members of the miR-29s family were significantly 
reduced in cancer tissues. Moreover, restoration of miR-29s strongly inhibited cancer cell 
migration and invasion. Thus, the miR-29s family functions as a group of tumour suppressors,
and they might contribute to metastasis in HNSCC.
To elucidate the silencing mechanisms of miR-29s in HNSCC cells, we performed 
preliminary analysis of 5-Aza-dC treatment as a demethylation agent on HNSCC cells. Our data 
demonstrated that miR-29s were not recovered by the treatment (data not shown), suggesting 
that silencing of miR-29s were not caused by methylation of CpG islands on their genomic 
regions. Three annotated genes (CR1L, CD46 and C1orf32) are located around the 
miR-29b-2/miR-29c cluster region on human chromosome 1q32.2 (Supplementary figure 1). 
Our microarray expression data of HNSCC (GEO accession number; GSE 36951) showed that 
expression changes of the three genes were not observed in cancer tissues. According to the 
UniGene database, expression levels of other genes shown in Supplementary figure 1 are 
extremely low.
Although the molecular mechanism by which miR-29s is silenced in HNSCC is still 
unknown, some important studies have examined the promoter region of miR-29s in the human 
genome. The human miR-29b-1/miR-29a promoter region contains two putative E-box sites 
(MYC-binding site), a Gli-binding site and four NF-kB-binding sites. Increased expression of 
MYC silenced miR-29b-1/miR-29a expression in cholangiocarcinoma cells (Mott et al, 2010). 
Furthermore, NF-kB signalling, which is known to be activated in inflammation-related cancers,
directly repressed miR-29b-1/miR-29a promoter activity (Mott et al, 2010; Wang et al, 2008). 
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Recent data showed that GATA3, a transcription factor promotes differentiation, suppresses 
metastasis and alters the tumor microenvironment in breast cancer by inducing miR-29b
expression (Chou et al, 2013). Thus, it will be necessary to identify the transcription factors
contributing to HNSCC. Further detailed analysis is needed to understand the molecular 
mechanisms of miR-29s silencing in HNSCC cells.
Metastasis is the final stage of cancer progression and is the cause of most cancer deaths. 
The epithelial to mesenchymal transition (EMT) is considered to be an important step in cancer 
progression and metastasis, and TGF- signalling contributes to EMT processes (Heldin et al, 
2012). Recent data have suggested that TGF-1 inhibits the expression of miR-29s and 
promotes the expression of extracellular matrix (ECM) components (Maurer et al, 2010; 
Roderburg et al, 2011). These data suggest that miR-29s could play an important role in 
modulating TGF- signalling during cancer cell migration and invasion. It will be of interest to 
more fully identify the molecular targets and pathways of miR-29s in HNSCC, particularly those 
contributing to cancer cell migration and invasion.
miRNAs are unique in their ability to regulate many protein coding genes. Bioinformatic 
predictions indicate that miRNAs regulate more than 30% of protein coding genes (Lewis et al, 
2005). We have taken the position that the identification of novel cancer pathways and 
responsible genes regulated by tumour suppressive miR-29s is an important first step in 
understanding HNSCC oncogenesis. Based on this view, we categorised miR-29s target genes 
into known pathways using the KEGG Pathway Database. These data have facilitated the 
understanding of tumour suppressive miRNA-regulated molecular pathways in human cancer. 
We devised this method of analysis and found that tumour suppressive miRNA could efficiently 
regulate cancer-associated pathways (Kinoshita et al, 2012; Nohata et al, 2013; Yoshino et al, 
2013).
In this study, we focused on the “focal adhesion” pathway because restoration of miR-29s
inhibited cancer cell migration and invasion in HNSCC cell lines. Cell adhesion is the binding 
of a cell to a surface, such as an extracellular matrix or another cell, and fundamental 
determinant of wide range of cell biology response and signaling (Parsons et al, 2010). Recent 
evidences suggested that several miRNAs including miR-29s regulated multiple molecular 
components of the cell adhesion machinery and contributed to functional key regulators of 
adhesion-associated processes (Valastyan and Weinberg, 2011). Our hypothesis is that 
downregulation of tumour suppressive miRNAs in cancer cells leads to upregulation of 
oncogenes. Therefore, we combined the gene expression data of miR-29a transfectants and the 
GEO expression data of upregulated genes in HNSCC, generating 16 candidate target genes for 
miR-29s in focal adhesion pathways. We focused on laminin 2 (LAMC2), a member of 
laminin-332, and 6 integrin (ITGA6) as responsible genes that contribute to cancer cell 
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migration and invasion in HNSCC. Numerous clinical studies indicated that overexpression of 
LAMC2 was positively correlated with invasiveness and poor survival in several types of cancer 
(Guess and Quaranta, 2009), suggesting LAMC2 function as an oncogene and deeply 
contributes to cancer metastasis. Because of the small number of the HNSCC samples, no 
positive data was obtained between clinical significance of the HNSCC patients and the LAMC2
and ITGA6 expression levels in the present study. Further examination should be necessary to 
elucidate expression levels of LAMC2 and ITGA6 and clinico-pathological parameters and 
patient survival of HNSCC.
Integrins are a large family of cell surface receptors composed of two subunits ( and ) 
that bind to ECM components. Most types of cells require integrin-mediated signal pathways 
for proliferation, migration, invasion and survival. To date, a total of 18 different  and 8 
different  subunits have been identified, accounting for at least 24 distinct integrin 
heterodimers (Gilcrease, 2007). Among those integrins, laminin-332 interacts with two major 
integrin receptors, 31 and 64, promoting the formation of focal adhesions and stable 
anchoring contacts (Marinkovich, 2007). 64 integrin is reportedly involved as a link between 
the cytoskeleton and ECM as well as in the activation of a variety of intercellular signalling
processes in cooperation with growth factor receptors (Falcioni et al, 1997; Mariotti et al, 2001; 
Trusolino et al, 2001). 
Of particular interest, laminin-332 and 64 integrin interaction triggers a number of 
signalling cascades in cancer cells, promoting both cell migration and cancer cell survival 
(Marinkovich, 2007). Furthermore, our previous data demonstrated that tumour suppressive 
miR-218, which was frequently reduced in HNSCC, directly regulated laminin-332, suggesting
that miR-218 contributed to cancer cell migration and invasion through regulating focal 
adhesion pathways (Kinoshita et al, 2012). Thus, the available data suggest that tumour
suppressive miR-29s and miR-218 contribute to cancer cell migration and invasion through their 
regulation of focal adhesion pathways, especially targeting laminin-332 and 64 integrin 
signalling (Figure 6). Evidence indicates that integrins crosstalk with receptor tyrosine kinases 
in an integrin type-dependent manner through a variety of specific mechanisms (Falcioni et al, 
1997; Mariotti et al, 2001; Trusolino et al, 2001). Thus, the understanding of tumour
suppressive miRNAs (miR-29s and miR-218) and their regulation of laminin-integrin signalling
should shed light on HNSCC metastasis as well as delineate more effective strategies for future 
therapeutic interventions for this disease.
Conclusions
Our data showed that all members of the miR-29s group were frequently downregulated 
in HNSCC. They function as tumour suppressors and normally inhibit cancer cell migration and 
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invasion through their regulation of focal adhesion pathways, especially via laminin-332 and 
64 integrin. Elucidation of cancer pathways regulated by tumour suppressive miR-29s should 
shed light on HNSCC metastasis as well as delineate more effective strategies for future 
therapeutic interventions for this disease.
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Titles and legends to figures
Figure 1.
Expression levels of miR-29s in HNSCC clinical specimens
(A) Expression levels of miR-29a, miR-29b and miR-29c in HNSCC clinical specimens were 
measured by qRT-PCR. RNU48 was used for normalisation. (B) Correlation between 
miR-29a-miR-29b and miR-29b-miR-29c were determined in HNSCC specimens.
Figure 2.
Effect of miR-29s transfection on cell proliferation, migration and invasion in SAS and 
FaDu.
(A) Cell proliferation 72 h after transfection with miR-29s (ten nM) was determined with the 
XTT assay. (B) Cell migration activity 48 h after transfection with miR-29s (ten nM) was 
determined with the migration assay. (C) Cell invasion activity 48 h after transfection with 
miR-29s (ten nM) was determined with the Matrigel invasion assay. *P < 0.005.
Figure 3.
Direct regulation of LAMC2 by miR-29s.
(A) LAMC2 mRNA expression 72 h after transfection with ten nM miR-29s in SAS was 
evaluated with qRT-PCR. GUSB was used as an internal control. **P < 0.005 (B) LAMC2 
protein expression 72 h after transfection with miR-29s in SAS was evaluated with Western blot 
analysis. GAPDH was used as a loading control. The expression ratio of LAMC2/GAPDH was 
calculated with ImageJ software. (C) TargetScan database analysis indicated two putative 
miR-29s binding sites existed in the LAMC2 3’-UTR (positions 611 - 627 and 1430 - 1436). 
With regard to these two sites, partial wild-type sequences of LAMC2 3’-UTR and those with 
the deleted miR-29s target sites were constructed and inserted between the XhoI – PmeI 
restriction sites in the 3’-UTR of the hRluc gene in the psiCHECK-2 vector. (D) The vectors 
were co-transfected with miR-29s or miR-control into SAS cells. Firefly luciferase activity was 
normalised to Renilla luciferase activity. Relative luciferase activity in miR-29s transfectants 
was compared with that in miR-control cultures, which was set at 1, in cells transfected with 
wild type-3’UTR or deletion-3’UTR. *P < 0.0083
Figure 4.
Direct regulation of ITGA6 by miR-29s.
(A) ITGA6 mRNA expression 72 h after transfection with ten nM miR-29s in SAS was 
evaluated with qRT-PCR. GUSB was used as an internal control. **P < 0.005 (B) ITGA6 
protein expression 72 h after transfection with miR-29s in SAS was evaluated with Western blot 
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analysis. GAPDH was used as a loading control. The expression ratio of ITGA6/GAPDH was 
calculated with ImageJ software. (C) TargetScan database analysis indicated a putative miR-29s
binding site existed in the ITGA6 3’-UTR (positions 1570 - 1576). With regard to this site, 
partial wild-type sequences of ITGA6 3’-UTR and those with the deleted miR-29s target site 
were constructed and inserted between the XhoI – PmeI restriction sites in the 3’-UTR of the 
hRluc gene in psiCHECK-2 vector. (D) The vectors were co-transfected with miR-29s or 
miR-control into SAS cells. Firefly luciferase activity was normalised to Renilla luciferase 
activity. Relative luciferase activity in miR-29s transfectants was compared with that in 
miR-control cultures, which was set at 1, in cells transfected with wild type-3’UTR or 
deletion-3’UTR. *P < 0.0083
Figure 5.
Effect of si-LAMC2 or si-ITGA6 transfection on cell proliferation, migration and invasion 
in SAS.
Cell proliferation 72 h after transfection with ten nM si-LAMC2 (A) or si-ITGA6 (B) in SAS 
was determined with the XTT assay. Cell migration activity 48 h after transfection with ten nM 
si-LAMC2 (C) or si-ITGA6 (D) in SAS was determined with the migration assay. Cell invasion 
activity 48 h after transfection with ten nM si-LAMC2 (E) or si-ITGA6 (F) in SAS was 
determined with the Matrigel invasion assay. *P < 0.0167.
Figure 6.
Illustration of tumour suppressive miR-29s and miR-218 regulation of laminin-332 and 
α6ß4 integrin.
Regulation of laminin-332 and α6ß4 integrin by miR-29s and miR-218 is shown (modified a 
figure in Guess and Quaranta, 2009). Laminin-332, which consists of laminin α3, ß3 and γ2 
chains, is a major component of basement membranes, but is also an important autocrine ligand 
produced by cancer cells to promote tumorigenesis. Laminin-332-α6ß4 integrin interaction 
promotes tumour invasion and survival by activation of PI3K and RAC1. LAMC2 and ITGA6 
were directly regulated by tumour suppressive miR-29s, while LAMB3 is directly regulated by 
tumour suppressive miR-218 (our previous study). In addition, ITGB4 has a putative miR-218
binding site in the 3’-UTR region.
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Table 1. Candidate target genes for miR-29s  in focal adhesion pathway.
Gene expression
analysis of SAS
Log2 ratio
(Tumour
/Normal)
P  value
Log2 ratio
(miR-29a
/miR-control)
LAMC2 3918 3.27 3.91E-06 -1.18
COL4A6 1288 2.60 2.12E-06 -0.87
COL4A1 1282 2.26 2.11E-04 -1.78
ITGA6 3655 2.07 7.10E-06 -1.62
COL11A1 1301 1.97 1.88E-03 -0.75
COL5A2 1290 1.74 3.87E-04 -3.18
COL4A2 1284 1.63 1.22E-03 -1.76
COL1A2 1278 1.45 6.95E-04 -0.61
COL6A3 1293 1.35 5.72E-03 -0.80
COL5A1 1289 1.23 1.69E-03 -1.56
COL3A1 1281 1.18 9.15E-03 -0.78
COL4A5 1287 1.14 5.52E-04 -0.96
COL5A3 50509 0.76 9.15E-03 -0.70
THBS2 7058 0.76 6.85E-02 -1.14
CAV2 858 0.55 5.15E-02 -0.81
CDC42 998 0.54 7.60E-03 -0.70
Gene
Symbol
Entrez
Gene ID
GEO expression data
(GSE9844)
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